NEW YORK, May 26, 2021 /PRNewswire/ -- Bruderman Brothers, LLC ("Bruderman Brothers"), is pleased to announce the successful sale of HealthEx Corporation ("HealthEx") to Associated Courier, Inc. ("ACI ...
13d
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement
SELLAS Life Sciences Group (SLS) has entered an agreement with IMPACT-AML, a pan-European clinical network, to run a new study of its CDK9 inhibitor SLS009 in high-risk newly diagnosed acute myeloid ...
The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.
Fintel reports that on September 7, 2023, Cantor Fitzgerald reiterated coverage of SELLAS Life Sciences Group (NASDAQ:SLS) with a Overweight recommendation. As of August 31, 2023, the average one-year ...
SELLAS Life Sciences Group recently reported that its Phase 3 REGAL trial of galinpepimut‑S (GPS) in Acute Myeloid Leukemia had reached 72 of the 80 overall-survival events required for final analysis ...
SELLAS Life Sciences Group Inc. Times Square Tower 7 Times Square Suite 2503 New York, New York 10026 Phone1 646 200-5278 IndustryBiotechnology SectorHealth Care/Life Sciences Fiscal Year-end12/2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results